2024-10-07 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of healthcare products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (ABT):** 101.67%
* **Cumulative Return (VOO):** 133.14%
* **Performance Gap:** -31.47% 
* **Relative Performance:** 11.58% (This means that ABTâ€™s performance is currently at the 11.58th percentile of its historical performance compared to VOO, indicating a below average performance.)

**2. Recent Price Movement:**

* **Closing Price:** $112.64
* **5-Day Moving Average:** $113.22
* **20-Day Moving Average:** $114.67
* **60-Day Moving Average:** $110.79

**3. Technical Indicators:**

* **RSI (Relative Strength Index):** 28.11 (Indicates oversold conditions, suggesting a potential for a price rebound.)
* **PPO (Percentage Price Oscillator):** -0.39 (Indicates a bearish trend, suggesting further downward movement.)
* **Delta_Previous_Relative_Divergence:** -11.95 (Indicates a short-term downtrend.)
* **Expected Return:** 0.0% (The maximum expected return over the next 5 years, relative to the S&P 500 (VOO), is currently estimated at 0%.)

**4. Recent Earnings and Outlook:**

| Date       | EPS  | Revenue    |
|------------|------|------------|
| 2024-07-31 | 0.74 | $10.38 B  |
| 2024-05-02 | 0.7  | $9.96 B   |
| 2023-11-01 | 0.82 | $10.14 B  |
| 2023-08-03 | 0.79 | $9.98 B   |
| 2024-07-31 | 0.79 | $9.98 B   |

* The most recent earnings (2024-07-31) reported EPS of 0.74, slightly beating analysts' expectations.  Revenue also exceeded estimates at $10.38 billion. 
* Abbott's earnings growth has been consistent in recent quarters, driven by strong performance in its medical devices, diagnostics, and pharmaceuticals businesses.
* Looking forward, analysts anticipate continued growth in the coming years, driven by increasing demand for healthcare products and services globally.

**5. News and Recent Issues:**

**Recent Market Outlook:**

* Abbott Laboratories' stock is currently experiencing a period of volatility, influenced by factors such as inflation, interest rate hikes, and economic uncertainty. 
* However, the company's strong fundamentals, including its diverse portfolio of products and global presence, continue to provide support for its stock price.

**Analyst Opinions and Performance Highlights:**

* **FINBOLD**:  FINBOLD reports a "Hold" recommendation for Abbott Laboratories, citing the company's strong financials and consistent growth. However, they also highlight potential risks related to regulatory changes and competition within the healthcare industry.

**6. Comprehensive Analysis:**

Abbott Laboratories is a well-established healthcare company with a strong track record of growth and profitability. However, its stock has been underperforming compared to the broader market (S&P 500) in recent months. Technical indicators suggest that the stock is currently oversold and may be due for a rebound. 

While the company's earnings have been strong, the current economic environment poses some uncertainties. The company's consistent growth, diverse product portfolio, and strong fundamentals provide a long-term outlook for investors.  

**7. Recommendations:**

* **Short-Term:**  Given the oversold conditions and potential for a rebound, a short-term buy signal is possible.
* **Long-Term:** Abbott Laboratories remains a solid investment for long-term investors seeking exposure to the healthcare sector. Its consistent growth, diverse product portfolio, and global presence position it well for future success.
* **Investors should continue to monitor the company's progress and any potential risks to its business, such as regulatory changes or competition.**

**Disclaimer:** This information is for educational purposes only and should not be considered financial advice. 
